These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9643566)

  • 1. Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance.
    Meckenstock G; Aul C; Hildebrandt B; Heyll A; Germing U; Wehmeier A; Giagounidis A; Suedhoff T; Burk M; Soehngen D; Schneider W
    Leuk Lymphoma; 1998 May; 29(5-6):523-31. PubMed ID: 9643566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
    Gahn B; Haase D; Unterhalt M; Drescher M; Schoch C; Fonatsch C; Terstappen LW; Hiddemann W; Büchner T; Bennett JM; Wörmann B
    Leukemia; 1996 Jun; 10(6):946-51. PubMed ID: 8667650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.
    Schmetzer HM; Braun S; Wiesner D; Duell T; Gerhartz HH; Mittermueller J
    Acta Haematol; 2000; 103(3):125-34. PubMed ID: 10940650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
    Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
    Perea G; Domingo A; Villamor N; Palacios C; Juncà J; Torres P; Llorente A; Fernández C; Tormo M; Queipo de Llano MP; Bargay J; Gallart M; Florensa L; Vivancos P; Martí JM; Font L; Berlanga J; Esteve J; Bueno J; Ribera JM; Brunet S; Sierra J; Nomdedéu JF;
    Leuk Res; 2005 Oct; 29(10):1109-16. PubMed ID: 16095690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings.
    Cuneo A; Ferrant A; Michaux JL; Boogaerts M; Demuynck H; Van Orshoven A; Criel A; Stul M; Dal Cin P; Hernandez J
    Blood; 1995 Jun; 85(12):3688-94. PubMed ID: 7780152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
    de Nully Brown P; Jurlander J; Pedersen-Bjergaard J; Victor MA; Geisler CH
    Leuk Res; 1997 Oct; 21(10):985-95. PubMed ID: 9403009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
    Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
    Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
    Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
    Iwakiri R; Ohta M; Mikoshiba M; Tsutsumi H; Kumakawa T; Mori M
    Int J Hematol; 2002 Jan; 75(1):45-50. PubMed ID: 11843290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.
    Cuneo A; Bigoni R; Cavazzini F; Bardi A; Roberti MG; Agostini P; Tammiso E; Ciccone N; Mancini M; Nanni M; De Cuia R; Divona M; La Starza R; Crescenzi B; Testoni N; Rege Cambrin G; Mecucci C; Lo Coco F; Saglio G; Castoldi G
    Leukemia; 2002 Sep; 16(9):1745-51. PubMed ID: 12200689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.